Sensitization of TRAIL-induced cell death by 20(S)- Ginsenoside Rg 3 via CHOP-mediated DR5 upregulation in human hepatocellular carcinoma cells

Ju Yeon Lee, Kyung Hee Jung, Michael J. Morgan, Yi Rae Kang, Hee Seung Lee, Gi Bang Koo, Soon Sun Hong, Sung Won Kwon, You Sun Kim

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

The TRAIL pathway is a potential therapeutic target for anticancer drugs due to selective cytotoxicity in cancer cells. Despite considerable promise, TRAIL or TRAIL receptor agonists have been used thus far with limited success in multiple clinical trials, in part due to acquired TRAIL resistance during chemotherapeutic treatment. Hepatocellular carcinoma (HCC) is a common solid tumor and the third leading cause of cancerrelated death worldwide. Classical chemotherapy is not effective for HCC treatment and targeted therapy is limited to sorafenib. Isolated from Panax ginseng CA Meyer, 20(S)-ginsenoside Rg 3 is a steroidal saponin with high pharmacologic activity that has been shown to sensitize cells to some chemotherapeutic agents. We investigated the sensitizing effect of Rg3 on TRAIL-induced cell death in HCC cells. We show Rg3 is capable of promoting TRAIL-induced apoptosis in a number of HCC cell lines, including HepG2, SK-Hep1, Huh-7, and Hep3B, but not in normal HL-7702 hepatocytes, indicating that Rg3 sensitization to TRAIL may be specific to cancer cells. Mechanistically, we found that Rg 3 upregulates DR5 expression at the transcriptional level. DR5 upregulation in this case is mediated by C/EBP homology protein (CHOP), an important endoplasmic reticulum stress responsive protein. Furthermore, Rg 3 is well tolerated and enhances the therapeutic efficacy of TRAIL in mouse xenograft models, suggesting that chemosensitization also occurs in vivo. Taken together, our study identifies Rg3 as a novel anticancer therapeutic agent and supports the further development of Rg3 as a chemosensitizer in combined therapy with TRAIL.

Original languageEnglish (US)
Pages (from-to)274-285
Number of pages12
JournalMolecular Cancer Therapeutics
Volume12
Issue number3
DOIs
StatePublished - Mar 2013

Fingerprint

CCAAT-Enhancer-Binding Proteins
Hepatocellular Carcinoma
Cell Death
Up-Regulation
Therapeutics
TNF-Related Apoptosis-Inducing Ligand Receptors
Neoplasms
Panax
Endoplasmic Reticulum Stress
Saponins
Heat-Shock Proteins
ginsenoside Rg3
Heterografts
Antineoplastic Agents
Cause of Death
Hepatocytes
Clinical Trials
Apoptosis
Drug Therapy
Cell Line

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Sensitization of TRAIL-induced cell death by 20(S)- Ginsenoside Rg 3 via CHOP-mediated DR5 upregulation in human hepatocellular carcinoma cells. / Lee, Ju Yeon; Jung, Kyung Hee; Morgan, Michael J.; Kang, Yi Rae; Lee, Hee Seung; Koo, Gi Bang; Hong, Soon Sun; Kwon, Sung Won; Kim, You Sun.

In: Molecular Cancer Therapeutics, Vol. 12, No. 3, 03.2013, p. 274-285.

Research output: Contribution to journalArticle

Lee, Ju Yeon ; Jung, Kyung Hee ; Morgan, Michael J. ; Kang, Yi Rae ; Lee, Hee Seung ; Koo, Gi Bang ; Hong, Soon Sun ; Kwon, Sung Won ; Kim, You Sun. / Sensitization of TRAIL-induced cell death by 20(S)- Ginsenoside Rg 3 via CHOP-mediated DR5 upregulation in human hepatocellular carcinoma cells. In: Molecular Cancer Therapeutics. 2013 ; Vol. 12, No. 3. pp. 274-285.
@article{c7d3db793cb743899a5e766dc0521d09,
title = "Sensitization of TRAIL-induced cell death by 20(S)- Ginsenoside Rg 3 via CHOP-mediated DR5 upregulation in human hepatocellular carcinoma cells",
abstract = "The TRAIL pathway is a potential therapeutic target for anticancer drugs due to selective cytotoxicity in cancer cells. Despite considerable promise, TRAIL or TRAIL receptor agonists have been used thus far with limited success in multiple clinical trials, in part due to acquired TRAIL resistance during chemotherapeutic treatment. Hepatocellular carcinoma (HCC) is a common solid tumor and the third leading cause of cancerrelated death worldwide. Classical chemotherapy is not effective for HCC treatment and targeted therapy is limited to sorafenib. Isolated from Panax ginseng CA Meyer, 20(S)-ginsenoside Rg 3 is a steroidal saponin with high pharmacologic activity that has been shown to sensitize cells to some chemotherapeutic agents. We investigated the sensitizing effect of Rg3 on TRAIL-induced cell death in HCC cells. We show Rg3 is capable of promoting TRAIL-induced apoptosis in a number of HCC cell lines, including HepG2, SK-Hep1, Huh-7, and Hep3B, but not in normal HL-7702 hepatocytes, indicating that Rg3 sensitization to TRAIL may be specific to cancer cells. Mechanistically, we found that Rg 3 upregulates DR5 expression at the transcriptional level. DR5 upregulation in this case is mediated by C/EBP homology protein (CHOP), an important endoplasmic reticulum stress responsive protein. Furthermore, Rg 3 is well tolerated and enhances the therapeutic efficacy of TRAIL in mouse xenograft models, suggesting that chemosensitization also occurs in vivo. Taken together, our study identifies Rg3 as a novel anticancer therapeutic agent and supports the further development of Rg3 as a chemosensitizer in combined therapy with TRAIL.",
author = "Lee, {Ju Yeon} and Jung, {Kyung Hee} and Morgan, {Michael J.} and Kang, {Yi Rae} and Lee, {Hee Seung} and Koo, {Gi Bang} and Hong, {Soon Sun} and Kwon, {Sung Won} and Kim, {You Sun}",
year = "2013",
month = "3",
doi = "10.1158/1535-7163.MCT-12-0054",
language = "English (US)",
volume = "12",
pages = "274--285",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - Sensitization of TRAIL-induced cell death by 20(S)- Ginsenoside Rg 3 via CHOP-mediated DR5 upregulation in human hepatocellular carcinoma cells

AU - Lee, Ju Yeon

AU - Jung, Kyung Hee

AU - Morgan, Michael J.

AU - Kang, Yi Rae

AU - Lee, Hee Seung

AU - Koo, Gi Bang

AU - Hong, Soon Sun

AU - Kwon, Sung Won

AU - Kim, You Sun

PY - 2013/3

Y1 - 2013/3

N2 - The TRAIL pathway is a potential therapeutic target for anticancer drugs due to selective cytotoxicity in cancer cells. Despite considerable promise, TRAIL or TRAIL receptor agonists have been used thus far with limited success in multiple clinical trials, in part due to acquired TRAIL resistance during chemotherapeutic treatment. Hepatocellular carcinoma (HCC) is a common solid tumor and the third leading cause of cancerrelated death worldwide. Classical chemotherapy is not effective for HCC treatment and targeted therapy is limited to sorafenib. Isolated from Panax ginseng CA Meyer, 20(S)-ginsenoside Rg 3 is a steroidal saponin with high pharmacologic activity that has been shown to sensitize cells to some chemotherapeutic agents. We investigated the sensitizing effect of Rg3 on TRAIL-induced cell death in HCC cells. We show Rg3 is capable of promoting TRAIL-induced apoptosis in a number of HCC cell lines, including HepG2, SK-Hep1, Huh-7, and Hep3B, but not in normal HL-7702 hepatocytes, indicating that Rg3 sensitization to TRAIL may be specific to cancer cells. Mechanistically, we found that Rg 3 upregulates DR5 expression at the transcriptional level. DR5 upregulation in this case is mediated by C/EBP homology protein (CHOP), an important endoplasmic reticulum stress responsive protein. Furthermore, Rg 3 is well tolerated and enhances the therapeutic efficacy of TRAIL in mouse xenograft models, suggesting that chemosensitization also occurs in vivo. Taken together, our study identifies Rg3 as a novel anticancer therapeutic agent and supports the further development of Rg3 as a chemosensitizer in combined therapy with TRAIL.

AB - The TRAIL pathway is a potential therapeutic target for anticancer drugs due to selective cytotoxicity in cancer cells. Despite considerable promise, TRAIL or TRAIL receptor agonists have been used thus far with limited success in multiple clinical trials, in part due to acquired TRAIL resistance during chemotherapeutic treatment. Hepatocellular carcinoma (HCC) is a common solid tumor and the third leading cause of cancerrelated death worldwide. Classical chemotherapy is not effective for HCC treatment and targeted therapy is limited to sorafenib. Isolated from Panax ginseng CA Meyer, 20(S)-ginsenoside Rg 3 is a steroidal saponin with high pharmacologic activity that has been shown to sensitize cells to some chemotherapeutic agents. We investigated the sensitizing effect of Rg3 on TRAIL-induced cell death in HCC cells. We show Rg3 is capable of promoting TRAIL-induced apoptosis in a number of HCC cell lines, including HepG2, SK-Hep1, Huh-7, and Hep3B, but not in normal HL-7702 hepatocytes, indicating that Rg3 sensitization to TRAIL may be specific to cancer cells. Mechanistically, we found that Rg 3 upregulates DR5 expression at the transcriptional level. DR5 upregulation in this case is mediated by C/EBP homology protein (CHOP), an important endoplasmic reticulum stress responsive protein. Furthermore, Rg 3 is well tolerated and enhances the therapeutic efficacy of TRAIL in mouse xenograft models, suggesting that chemosensitization also occurs in vivo. Taken together, our study identifies Rg3 as a novel anticancer therapeutic agent and supports the further development of Rg3 as a chemosensitizer in combined therapy with TRAIL.

UR - http://www.scopus.com/inward/record.url?scp=84874859650&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874859650&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-12-0054

DO - 10.1158/1535-7163.MCT-12-0054

M3 - Article

C2 - 23053497

AN - SCOPUS:84874859650

VL - 12

SP - 274

EP - 285

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 3

ER -